BioCentury | Jan 3, 2020
Emerging Company Profile

Click: personalized digital therapeutics for cognitive, neurobehavioral disorders

Click is developing a pipeline of personalized prescription digital therapeutics that could be used alone or in combination with traditional therapeutics to treat cognitive and neurobehavioral disorders. Launched in 2012, Click Therapeutics Inc. markets a...
BioCentury | Dec 12, 2019
Clinical News

PureTech’s Akili reports positive data for depression video game

In a busy week for PureTech affiliates, Akili reported data for its video game-based digital therapeutic to help treat cognitive impairments associated with depression. PureTech Health plc (LSE:PRTC) founded Akili Interactive Labs Inc., which raised...
BioCentury | Nov 16, 2019
Product Development

Navigating IP strategies in the world of digital therapeutics

For digital therapeutics, which straddle life sciences and tech, IP may be less important to creating value than the data they generate. As biopharma companies move into the world of digital therapeutics, they will need...
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BioCentury | Mar 14, 2019
Company News

Akili creates global access platform for digital therapeutics, grants Shionogi license

Shionogi gained exclusive rights to develop and commercialize Akili's digital therapeutics for ADHD and autism spectrum disorder (ASD) in Japan and Taiwan. Akili Interactive Labs Inc. (Boston, Mass.) will receive $20 million up front and...
BioCentury | Mar 22, 2012
Cover Story

Bioartificial pancreas beta test

Beta-O2 Technologies Ltd. and an international team of academic collaborators have shown that the company's bioartificial pancreas can house donor islets, supply them with oxygen and protect them from the host immune system in vivo...
BioCentury | Jan 5, 2009
Finance

Follow-on performance

Follow-on performance Company Date Raised Post-$ 12/31 mcap % chg SkyePharma (LSE:SKP) (A) 9/25/08 $38.8 $61.3 $45.2 -26% Vertex (NASDAQ:VRTX) 9/18/08 $219.9 $3,818.5 $4,547.9 19% Acorda (NASDAQ:ACOR) 8/7/08 $131.1 $1,072.7 $771.2 -28% Illumina (NASDAQ:ILMN) 8/7/08...
BioCentury | Nov 17, 2008
Regulation

Opioid abuse-deterrence pipeline

Opioid abuse-deterrence pipeline Company Name Compound Abuse deterrent technology Status Alpharma (NYSE:ALO) Embeda (morphine) Extended-release formulation includes a sequestered pellet core of naltrexone Registration Pain Therapeutics (NASDAQ:PTIE)/ King (NYSE:KG)/Durect (NASDAQ:DRRX) Remoxy (oxycodone) Durect's Oradur technology...
BioCentury | May 12, 2008
Regulation

Fentanyl pipeline

Fentanyl pipeline Company Product Indication Status Cephalon (NASDAQ:CEPH) Actiq fentanyl Breakthrough pain (BTP) in opioid- tolerant cancer patients Mkt Cephalon Fentora fentanyl BTP in opioid-tolerant cancer patients; BTP in opioid-tolerant non-cancer patients Mkt (cancer); registration...
BioCentury | Mar 10, 2008
Clinical News

EDACS: Phase I started

Akela began an open-label, single-dose, Asian Phase I trial to compare 3 extended-release formulations of an undisclosed opioid with an immediate-release formulation of the same opioid in 12 healthy volunteers. Akela Pharma Inc. (TSX:AKL), St....
Items per page:
1 - 10 of 27